Treatment-resistant depression (TRD) is a severe form of depression that
persists despite the use of at least two adequate antidepressant treatments.
This condition, affecting approximately one-third of depressed patients,
represents a significant challenge in psychiatry. TRD is associated with
significantly reduced quality of life, increased risk of comorbidities,
including anxiety and cardiovascular diseases, and higher mortality rates.
Despite the benefits of current treatments, their effectiveness remains
limited for these patients, highlighting an
urgent need for alternative
solutions. These new approaches must target biological mechanisms often
overlooked by conventional treatments while offering innovative and
personalized options.
In this context, the
ketogenic diet emerges as a promising avenue to
complement or enhance conventional therapies. Known for its
neuroprotective
effects and its
beneficial impact on gut microbiota, this diet—based on low
carbohydrate and high fat consumption—stimulates the production of ketone
bodies. These molecules play a crucial role in
regulating brain functions by
improving neuronal balance, reducing oxidative stress, and modulating
inflammatory processes.
This study explores the efficacy and mechanisms of the ketogenic diet as
a complementary treatment for treatment-resistant depression.
Read next: Winter
Blues: How Lifestyle Makes the Difference
The Ketogenic Diet: A Remedy That Lives Up to Its Promises?
In this study, patients aged 18 to 65 with TRD were randomly divided
into two groups:
- Ketogenic
Diet Group (KD):
Carbohydrate intake limited to 30g per day, with meals prepared and weekly
monitoring by a dietitian. Ketosis levels were regularly measured to
assess adherence.
- Control
Group (Plant-Based Diet):
Similar monitoring but based on a diet richer in vegetables and
unsaturated fats.
The study lasted six weeks, with rigorous follow-up to evaluate
participant adherence. Depressive symptoms were assessed at 6 and 12 weeks.
Secondary parameters included anxiety, quality of life, reward sensitivity, and
changes in gut microbiota.
Participants following the ketogenic diet showed
a significant reduction
in depression scores at six weeks compared to the control group. Improvements
were also observed in secondary aspects such as anxiety and anhedonia.
The data also suggest that the ketogenic diet influences several
biological mechanisms. It
stimulates the production of the neurotransmitter
GABA, essential for the balance between neuronal excitation and inhibition,
thereby reducing brain dysfunctions associated with depression. Ketone bodies
produced by this diet exert
protective effects against oxidative stress.
Beneficial changes in gut microbiota were also observed, promoting the
growth
of bacteria linked to better mental health.
The Ketogenic Diet: A Revolution in Progress
TRD is a severe form of depression that persists despite the use of
antidepressants. Affecting about one-third of depressed patients, it leads to
reduced quality of life and increased risks of comorbidities.
Faced with these challenges,
the ketogenic diet appears as an innovative
approach, targeting biological mechanisms such as neurotransmitter balance,
oxidative stress reduction, and gut microbiota improvement. This study aimed to
evaluate its efficacy and potential as a complementary treatment by comparing a
ketogenic diet group with a control group receiving a more conventional diet.
The results show that
the ketogenic diet significantly improves
depressive symptoms, particularly anxiety and anhedonia. However, its impact
depends on
strict adherence, which poses a significant challenge for its
clinical implementation.
Larger-scale studies with extended follow-up are necessary to confirm
these findings and identify strategies to enhance patient adherence. If these
obstacles are overcome, the ketogenic diet could expand current therapeutic
options, offering a promising new path for patients with TRD.
